Patients with sickle cell disease and beta-thalassemia treated with exagamglogene autotemcel reported substantial and ...
Despite an incredibly challenging quarter from a factor perspective, Q3 was another strong period for the Fund.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback